search
Back to results

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

Primary Purpose

Plaque Psoriasis

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Etanercept
CHS-0214
Sponsored by
Coherus Biosciences, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Plaque Psoriasis focused on measuring PsO

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female adults
  • PsO diagnosis for 6 months
  • Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale or 0-5),
  • Body Surface Area (BSA) involved with PsO greater than or equal to 10%
  • Dermatology Life Quality Index (DQLI) greater than or equal to 10
  • Previously received phototherapy or systemic non-biologic therapy for PsO

Exclusion Criteria:

  • Forms of Psoriasis other than PsO
  • Drug induced Psoriasis
  • Positive QuantiFERON-tuberculosis (TB) Gold Test
  • Presence of significant comorbid conditions
  • Chemistry and hematology values outside protocol specified range
  • Major systemic infections

Sites / Locations

  • Arizona Research Center
  • Radiant Research - Scottsdale
  • Anaheim Clinical Trials
  • Dream Team Clinical Research
  • Private Practice
  • Kaiser Permanente
  • Skin Surgery Medical Group, Inc
  • Clinical Science Institute
  • Healthcare Partners Medical Group
  • Horizons Clinical Research Center
  • The Savin Center
  • New England Research Associates
  • Florida Academic Dermatology Center (U of Miami Hospital)
  • Radiant Research - Pinellas Park
  • Atlantic Clinical Research Collaborative
  • Palm Beach Research Center
  • Radiant Research - Atlanta
  • Private Practice - Jamie Weisman
  • Altman Dermatology Associates
  • Springfield Clinic
  • The Indiana Clinical Trials Center
  • Kansas City Dermatology
  • Derm Research
  • Hamzavi Dermatology Clinical Research
  • Grekin Skin Institute
  • Radiant Research - Edina
  • Central Dermatology
  • The Psoriasis Treatment Center of Central New Jersey
  • Skin Search of Rochester, Inc
  • DermResearch Center of New York
  • PMG Research of Carey, LLC
  • DJL Clinical Research
  • PMG Research of Wilmington
  • Radiant Research
  • Health Research of Oklahoma
  • Altoona Center for Clincal Research
  • Clinical Research Center of Reading
  • Radiant Research - Anderson
  • Dermatology and Laser Center of Charleston
  • Radient Research - Greer
  • Rivergate Dermatology
  • Neighborhood Medical Center
  • Center for Clinical Studies
  • Heights Dermatology and Aesthetic Center
  • Progressive Clinical Research - San Antonio
  • Center for Clinical Studies
  • Dermatology Associates, PLLC
  • Premier Clinical Research
  • Wenatchee Valley Hospital and Clinics
  • Mountain State Clinical Research
  • Woden Dermatology Pty
  • Dr S P Shumack (St George Dermatology and Skin Cancer Center)
  • Dr S P Shumack (Central Sydney Dermatology)
  • North Eastern Health Specialists
  • Sinclair Dermatology
  • E and D Woolner Professional Corporation
  • Institute for Skin Advancement Inc
  • CCA Medical Research Corporation
  • Lynderm Research Inc
  • North Bay Dermatology Centre Inc
  • Institute of Cosmetic and Laser Surgery
  • SKiN Center for Dermatology
  • Private Practice
  • Research Toronto
  • K. Papp Clinical Research Inc
  • MVZ Reichenberger Str., Aerztehaus "Rudolf Virchow
  • Klinische Forschung Dresden GmbH
  • Hautklinik Universitaetsklinikum Erlangen
  • Johann Wolfgang Hospital - Goethe University
  • Dermatologikum Hamburg
  • University Hospital Schleswig-Holstein - Campus Luebeck
  • Haemek Medical Center
  • Rambam Health Care Campus
  • Rabin Medical Center Beilinson Campus
  • Tel Aviv Sourasky Medical Center
  • NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik
  • Niepubliczny Zaklad Opieki Zdrowotnej Centrum Osteoporozy i Chorób Kostno-Stawowych J. Badurski S.J
  • Centrum Badan Klinicznych PI-House Sp. Z o.o
  • Synexus Polska Sp. z o.o. Oddzial w Gdyni
  • Synexus Polska Sp. z o.o. Oddzial w Katowicach
  • Specjalistyczny Osrodek ALL-MED
  • Krakowskie Centrum Medyczne
  • Center Med
  • Specjalistyczne Gabinety Lekarskie "Dermed
  • Centrum Medyczne SYNEXUS POZNAN
  • Centrum Medyczne Medyk
  • SANUS Szpital Specjalistyczny Sp. z o.o
  • EuroMedis Sp. z o.o.
  • NZOZ "Nasz Lekarz" Praktyka Grupowa Lekarzy z Przychodnia Specjalistyczna
  • Synexus Polska Sp. z o.o. Oddzial w Warszawie
  • MTZ Clinical Research Sp. z o.o.
  • Synexus Polska sp. z o.o
  • Dermmedica Sp. z o.o
  • Vincent Pallotti Hospital
  • Synopsis Research
  • Jongaie Research
  • Helderberg Clinical Trial Centre
  • Dr IC Louw
  • Winelands Rheumatology Centre
  • Clinical Projects Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Enbrel (etanercept)

CHS-0214

Arm Description

Enbrel 50mg twice weekly times 12 weeks

CHS-0214 50mg twice weekly times 12 weeks

Outcomes

Primary Outcome Measures

Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12
The Psoriasis Area and Severity Index (PASI) is well established in the medical literature and is internationally the most widely used instrument to assess the severity of Psoriasis. Proportion of subjects achieving PASI-75 from baseline at Week 12. This was the primary endpoint supporting a Biologics Licensing Application in the US.
Mean Percent Change in PASI (Psoriasis Area and Severity Index) at 12 Weeks
Mean percent changed in PASI from baseline (last non-missing value prior to first dose) at Week 12. This was the primary endpoint supporting the Marketing Authorization Application in the EU.

Secondary Outcome Measures

Mean Percent Change in PASI (Psoriasis Area and Severity Index) From Baseline
Mean percent change in PASI from baseline at Weeks 4, 8, 12, 24, 36, and 48
Number of Participants Who Achieved PASI - 75 (75% Improvement in Psoriasis Area and Severity Index)
The proportion of subjects who achieved PASI-75 (75% Improvement in Psoriasis Area and Severity Index) from baseline at Weeks 4, 8, 12, 24, 36, and 48.
Number of Subjects Who Achieved a 50% Improvement in Psoriasis Area and Severity Index (PASI-50) and a 90% Improvement in PASI (PASI-90)
The proportion of subjects who achieved a 50% improvement in Psoriasis Area and Severity Index (PASI-50) and a 90% improvement in PASI (PASI-90) response rates from baseline at Weeks 4, 8, 12, 24, 36, and 48
Change in PSGA (Physician's Static Global Assessment) of Disease Activity on a Scale of 0 to 5
Change in PSGA (Physician's Static Global Assessment) of disease activity on a scale of 0 to 5 from baseline to Weeks 4, 8, 12, 24, 36, and 48. Minimum Value: 0 Maximum Value: 5 The PSGA of PsO (Psoriasis) was assessed on a scale of 0 to 5, with 0 indicating no PsO (clear of disease),1 (almost clear), and 2 or higher scores indicating more severe disease. Subjects with a clear (0) or almost clear (1) evaluation were considered PSGA responders.
The Proportion of Subjects With a Change in a PSGA (Physician's Static Global Assessment) Score = 0 to 1
The proportion of subjects with a change in a PSGA (Physician's Static Global Assessment) score = 0 to 1, demonstrating clear or almost clear skin at Weeks 4, 8, 12, 24, 36, and 48; Minimum: 0 Maximum: 1 Subjects with a clear(0) or almost clear(1) evaluation were considered PSGA responders.
Change in Subject's Global Assessment (SGA) of PsO
Change in Subject's Global Assessment (SGA) of PsO from baseline to Weeks 4, 8, 12, 24, 36, and 48. The SGA of PsO was assessed using VAS (visual analog scale in the unit of millimeters) , ranging from 0 (good) to 100 (severe). The SGA was assessed at randomization (Week 0/Day 0) and Weeks 4, 8, 12, 24, 36, and 48, as well as at the Follow-up Visit, if applicable. The change in SGA is the value at baseline minus sum of values at weeks 4, 8, 12, 24, 36, and 48. Since the change in SGA is measured from baseline, a negative value indicates a decrease in overall SGA and better overall assessment of PsO.
Change in DLQI (Dermatology Life Quality Index)
Change in DLQI (Dermatology Life Quality Index) from baseline to Weeks 12, 24, and 48 The DLQI is a 10-question validated questionnaire that was performed at screening, randomization (Week 0/Day 0), and Weeks 12, 24, and 48. It was calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life was impaired.
Change in EuroQol 5-Dimension Health Status Questionnaire (EQ-5D)
Change in EuroQol 5-Dimension Health Status Questionnaire (EQ-5D) from baseline to Weeks 12, 24, and 48 The EQ-5D was performed at randomization (Week 0/Day 0), and Weeks 12, 24, and 48. The EQ-5D is a generic (non-disease specific), preference-based health-related quality of life measure based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 33333 (having extreme problems in all dimensions).
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI)
HAQ-DI - Scales for each question range from 0-3 (0=without any difficulty; 1=with some difficulty; 2=with much difficulty; 3=Unable to do). The "total" for each category is determined by the highest score (greatest difficulty) for that category. The score for the disability index is the mean of the eight category scores. If more than 2 of the categories or 25% are missing, the scale won't be scored. If fewer than 2 or the categories are missing, the sum of the categories was divided by the number of answered categories.
Change in Highly Sensitive C-reactive Protein (Hs-CRP; mg/L)
Change in highly sensitive C-reactive protein (hs-CRP; mg/L) from baseline to Weeks 12, 24, and 48 for subjects with PsA (Psoriatic arthritis) only. Highly sensitive C-reactive protein For subjects with PsA, change in hs-CRP from baseline to Weeks 12, 24, and 48 was assessed.
The Proportion of Subjects With a Durability of Response at Week 48
The proportion of subjects with a durability of response during Part 2. Durability of response was defined as the maintenance of the PASI-50 or greater at Weeks 24, 36, and 48 when compared to baseline (Week 0).

Full Information

First Posted
May 7, 2014
Last Updated
June 7, 2019
Sponsor
Coherus Biosciences, Inc.
Collaborators
Shire
search

1. Study Identification

Unique Protocol Identification Number
NCT02134210
Brief Title
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
Official Title
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2019
Overall Recruitment Status
Completed
Study Start Date
June 16, 2014 (Actual)
Primary Completion Date
July 27, 2015 (Actual)
Study Completion Date
May 12, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Coherus Biosciences, Inc.
Collaborators
Shire

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).
Detailed Description
Pt. 1 is a 12-week randomized, double-blind, active-control, parallel-group, multi-center global study. The primary end point is 75% improvement from baseline according to the Psoriasis Area and Severity Index (PASI-75). Comparing CHS-0214 to Enbrel for efficacy and safety at a dosage of 50mg subcutaneous (Sc) twice weekly. Pt. 2 is a 40-week randomized, double-blind, active-control, parallel-group, multi-center global study where CHS-0214 and Enbrel dosage is reduced to 50mg Sc weekly for maintenance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Plaque Psoriasis
Keywords
PsO

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
521 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Enbrel (etanercept)
Arm Type
Active Comparator
Arm Description
Enbrel 50mg twice weekly times 12 weeks
Arm Title
CHS-0214
Arm Type
Experimental
Arm Description
CHS-0214 50mg twice weekly times 12 weeks
Intervention Type
Drug
Intervention Name(s)
Etanercept
Other Intervention Name(s)
Enbrel, European Enbrel
Intervention Description
Head-to-head comparison
Intervention Type
Drug
Intervention Name(s)
CHS-0214
Primary Outcome Measure Information:
Title
Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12
Description
The Psoriasis Area and Severity Index (PASI) is well established in the medical literature and is internationally the most widely used instrument to assess the severity of Psoriasis. Proportion of subjects achieving PASI-75 from baseline at Week 12. This was the primary endpoint supporting a Biologics Licensing Application in the US.
Time Frame
12-weeks
Title
Mean Percent Change in PASI (Psoriasis Area and Severity Index) at 12 Weeks
Description
Mean percent changed in PASI from baseline (last non-missing value prior to first dose) at Week 12. This was the primary endpoint supporting the Marketing Authorization Application in the EU.
Time Frame
12 Weeks
Secondary Outcome Measure Information:
Title
Mean Percent Change in PASI (Psoriasis Area and Severity Index) From Baseline
Description
Mean percent change in PASI from baseline at Weeks 4, 8, 12, 24, 36, and 48
Time Frame
Weeks 4, 8, 12, 24, 36, and 48
Title
Number of Participants Who Achieved PASI - 75 (75% Improvement in Psoriasis Area and Severity Index)
Description
The proportion of subjects who achieved PASI-75 (75% Improvement in Psoriasis Area and Severity Index) from baseline at Weeks 4, 8, 12, 24, 36, and 48.
Time Frame
Weeks 4, 8, 12, 24, 36, and 48
Title
Number of Subjects Who Achieved a 50% Improvement in Psoriasis Area and Severity Index (PASI-50) and a 90% Improvement in PASI (PASI-90)
Description
The proportion of subjects who achieved a 50% improvement in Psoriasis Area and Severity Index (PASI-50) and a 90% improvement in PASI (PASI-90) response rates from baseline at Weeks 4, 8, 12, 24, 36, and 48
Time Frame
Weeks 4, 8, 12, 24, 36, and 48
Title
Change in PSGA (Physician's Static Global Assessment) of Disease Activity on a Scale of 0 to 5
Description
Change in PSGA (Physician's Static Global Assessment) of disease activity on a scale of 0 to 5 from baseline to Weeks 4, 8, 12, 24, 36, and 48. Minimum Value: 0 Maximum Value: 5 The PSGA of PsO (Psoriasis) was assessed on a scale of 0 to 5, with 0 indicating no PsO (clear of disease),1 (almost clear), and 2 or higher scores indicating more severe disease. Subjects with a clear (0) or almost clear (1) evaluation were considered PSGA responders.
Time Frame
4, 8, 12, 24, 36, and 48
Title
The Proportion of Subjects With a Change in a PSGA (Physician's Static Global Assessment) Score = 0 to 1
Description
The proportion of subjects with a change in a PSGA (Physician's Static Global Assessment) score = 0 to 1, demonstrating clear or almost clear skin at Weeks 4, 8, 12, 24, 36, and 48; Minimum: 0 Maximum: 1 Subjects with a clear(0) or almost clear(1) evaluation were considered PSGA responders.
Time Frame
Weeks 4, 8, 12, 24, 36, and 48
Title
Change in Subject's Global Assessment (SGA) of PsO
Description
Change in Subject's Global Assessment (SGA) of PsO from baseline to Weeks 4, 8, 12, 24, 36, and 48. The SGA of PsO was assessed using VAS (visual analog scale in the unit of millimeters) , ranging from 0 (good) to 100 (severe). The SGA was assessed at randomization (Week 0/Day 0) and Weeks 4, 8, 12, 24, 36, and 48, as well as at the Follow-up Visit, if applicable. The change in SGA is the value at baseline minus sum of values at weeks 4, 8, 12, 24, 36, and 48. Since the change in SGA is measured from baseline, a negative value indicates a decrease in overall SGA and better overall assessment of PsO.
Time Frame
Weeks 4, 8, 12, 24, 36, and 48
Title
Change in DLQI (Dermatology Life Quality Index)
Description
Change in DLQI (Dermatology Life Quality Index) from baseline to Weeks 12, 24, and 48 The DLQI is a 10-question validated questionnaire that was performed at screening, randomization (Week 0/Day 0), and Weeks 12, 24, and 48. It was calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life was impaired.
Time Frame
Weeks 12, 24, and 48
Title
Change in EuroQol 5-Dimension Health Status Questionnaire (EQ-5D)
Description
Change in EuroQol 5-Dimension Health Status Questionnaire (EQ-5D) from baseline to Weeks 12, 24, and 48 The EQ-5D was performed at randomization (Week 0/Day 0), and Weeks 12, 24, and 48. The EQ-5D is a generic (non-disease specific), preference-based health-related quality of life measure based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 33333 (having extreme problems in all dimensions).
Time Frame
Weeks 12, 24, and 48
Title
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI)
Description
HAQ-DI - Scales for each question range from 0-3 (0=without any difficulty; 1=with some difficulty; 2=with much difficulty; 3=Unable to do). The "total" for each category is determined by the highest score (greatest difficulty) for that category. The score for the disability index is the mean of the eight category scores. If more than 2 of the categories or 25% are missing, the scale won't be scored. If fewer than 2 or the categories are missing, the sum of the categories was divided by the number of answered categories.
Time Frame
Weeks 12, 24, and 48
Title
Change in Highly Sensitive C-reactive Protein (Hs-CRP; mg/L)
Description
Change in highly sensitive C-reactive protein (hs-CRP; mg/L) from baseline to Weeks 12, 24, and 48 for subjects with PsA (Psoriatic arthritis) only. Highly sensitive C-reactive protein For subjects with PsA, change in hs-CRP from baseline to Weeks 12, 24, and 48 was assessed.
Time Frame
Weeks 12, 24, and 48
Title
The Proportion of Subjects With a Durability of Response at Week 48
Description
The proportion of subjects with a durability of response during Part 2. Durability of response was defined as the maintenance of the PASI-50 or greater at Weeks 24, 36, and 48 when compared to baseline (Week 0).
Time Frame
Weeks 24, 36, and 48 when compared to baseline (Week 0).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female adults PsO diagnosis for 6 months Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale or 0-5), Body Surface Area (BSA) involved with PsO greater than or equal to 10% Dermatology Life Quality Index (DQLI) greater than or equal to 10 Previously received phototherapy or systemic non-biologic therapy for PsO Exclusion Criteria: Forms of Psoriasis other than PsO Drug induced Psoriasis Positive QuantiFERON-tuberculosis (TB) Gold Test Presence of significant comorbid conditions Chemistry and hematology values outside protocol specified range Major systemic infections
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Barbara K Finck, M.D.
Organizational Affiliation
Coherus Biosciences, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Arizona Research Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85020
Country
United States
Facility Name
Radiant Research - Scottsdale
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85251
Country
United States
Facility Name
Anaheim Clinical Trials
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Dream Team Clinical Research
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Private Practice
City
Encino
State/Province
California
ZIP/Postal Code
91436
Country
United States
Facility Name
Kaiser Permanente
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Facility Name
Skin Surgery Medical Group, Inc
City
San Diego
State/Province
California
ZIP/Postal Code
92117
Country
United States
Facility Name
Clinical Science Institute
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Healthcare Partners Medical Group
City
Torrance
State/Province
California
ZIP/Postal Code
90503
Country
United States
Facility Name
Horizons Clinical Research Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80220
Country
United States
Facility Name
The Savin Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States
Facility Name
New England Research Associates
City
Trumbull
State/Province
Connecticut
ZIP/Postal Code
06611
Country
United States
Facility Name
Florida Academic Dermatology Center (U of Miami Hospital)
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Radiant Research - Pinellas Park
City
Pinellas Park
State/Province
Florida
ZIP/Postal Code
33781
Country
United States
Facility Name
Atlantic Clinical Research Collaborative
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33406
Country
United States
Facility Name
Palm Beach Research Center
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33409
Country
United States
Facility Name
Radiant Research - Atlanta
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30328
Country
United States
Facility Name
Private Practice - Jamie Weisman
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Altman Dermatology Associates
City
Arlington Heights
State/Province
Illinois
ZIP/Postal Code
60005
Country
United States
Facility Name
Springfield Clinic
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62703
Country
United States
Facility Name
The Indiana Clinical Trials Center
City
Plainfield
State/Province
Indiana
ZIP/Postal Code
46168
Country
United States
Facility Name
Kansas City Dermatology
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66215
Country
United States
Facility Name
Derm Research
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40217
Country
United States
Facility Name
Hamzavi Dermatology Clinical Research
City
Fort Gratiot
State/Province
Michigan
ZIP/Postal Code
48059
Country
United States
Facility Name
Grekin Skin Institute
City
Warren
State/Province
Michigan
ZIP/Postal Code
48093
Country
United States
Facility Name
Radiant Research - Edina
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55435
Country
United States
Facility Name
Central Dermatology
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63117
Country
United States
Facility Name
The Psoriasis Treatment Center of Central New Jersey
City
East Windsor
State/Province
New Jersey
ZIP/Postal Code
08520
Country
United States
Facility Name
Skin Search of Rochester, Inc
City
Rochester
State/Province
New York
ZIP/Postal Code
14623
Country
United States
Facility Name
DermResearch Center of New York
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11790
Country
United States
Facility Name
PMG Research of Carey, LLC
City
Cary
State/Province
North Carolina
ZIP/Postal Code
27518
Country
United States
Facility Name
DJL Clinical Research
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28210
Country
United States
Facility Name
PMG Research of Wilmington
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Radiant Research
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45249
Country
United States
Facility Name
Health Research of Oklahoma
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73103
Country
United States
Facility Name
Altoona Center for Clincal Research
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
Facility Name
Clinical Research Center of Reading
City
Wyomissing
State/Province
Pennsylvania
ZIP/Postal Code
19610
Country
United States
Facility Name
Radiant Research - Anderson
City
Anderson
State/Province
South Carolina
ZIP/Postal Code
29621
Country
United States
Facility Name
Dermatology and Laser Center of Charleston
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29414
Country
United States
Facility Name
Radient Research - Greer
City
Greer
State/Province
South Carolina
ZIP/Postal Code
29650
Country
United States
Facility Name
Rivergate Dermatology
City
Goodlettsville
State/Province
Tennessee
ZIP/Postal Code
37072
Country
United States
Facility Name
Neighborhood Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75254
Country
United States
Facility Name
Center for Clinical Studies
City
Houston
State/Province
Texas
ZIP/Postal Code
72004
Country
United States
Facility Name
Heights Dermatology and Aesthetic Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77008
Country
United States
Facility Name
Progressive Clinical Research - San Antonio
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Center for Clinical Studies
City
Webster
State/Province
Texas
ZIP/Postal Code
77598
Country
United States
Facility Name
Dermatology Associates, PLLC
City
Seattle
State/Province
Washington
ZIP/Postal Code
98101
Country
United States
Facility Name
Premier Clinical Research
City
Spokane
State/Province
Washington
ZIP/Postal Code
99204
Country
United States
Facility Name
Wenatchee Valley Hospital and Clinics
City
Wenatchee
State/Province
Washington
ZIP/Postal Code
98801
Country
United States
Facility Name
Mountain State Clinical Research
City
Clarksburg
State/Province
West Virginia
ZIP/Postal Code
26301
Country
United States
Facility Name
Woden Dermatology Pty
City
Phillip
State/Province
Australian Capital Territory
ZIP/Postal Code
2606
Country
Australia
Facility Name
Dr S P Shumack (St George Dermatology and Skin Cancer Center)
City
Kogarah
State/Province
New South Wales
ZIP/Postal Code
2217
Country
Australia
Facility Name
Dr S P Shumack (Central Sydney Dermatology)
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2000
Country
Australia
Facility Name
North Eastern Health Specialists
City
Hectorville
State/Province
South Australia
ZIP/Postal Code
5073
Country
Australia
Facility Name
Sinclair Dermatology
City
East Melbourne
State/Province
Victoria
ZIP/Postal Code
3002
Country
Australia
Facility Name
E and D Woolner Professional Corporation
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
Institute for Skin Advancement Inc
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
CCA Medical Research Corporation
City
Ajax
State/Province
Ontario
Country
Canada
Facility Name
Lynderm Research Inc
City
Markham
State/Province
Ontario
Country
Canada
Facility Name
North Bay Dermatology Centre Inc
City
North Bay
State/Province
Ontario
Country
Canada
Facility Name
Institute of Cosmetic and Laser Surgery
City
Oakville
State/Province
Ontario
Country
Canada
Facility Name
SKiN Center for Dermatology
City
Peterborough
State/Province
Ontario
Country
Canada
Facility Name
Private Practice
City
Richmond Hill
State/Province
Ontario
Country
Canada
Facility Name
Research Toronto
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
K. Papp Clinical Research Inc
City
Waterloo
State/Province
Ontario
Country
Canada
Facility Name
MVZ Reichenberger Str., Aerztehaus "Rudolf Virchow
City
Berlin
ZIP/Postal Code
13055
Country
Germany
Facility Name
Klinische Forschung Dresden GmbH
City
Dresden
ZIP/Postal Code
01069
Country
Germany
Facility Name
Hautklinik Universitaetsklinikum Erlangen
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Johann Wolfgang Hospital - Goethe University
City
Frankfurt
ZIP/Postal Code
60590
Country
Germany
Facility Name
Dermatologikum Hamburg
City
Hamburg
ZIP/Postal Code
20354
Country
Germany
Facility Name
University Hospital Schleswig-Holstein - Campus Luebeck
City
Luebeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
Haemek Medical Center
City
Afula
ZIP/Postal Code
18101
Country
Israel
Facility Name
Rambam Health Care Campus
City
Haifa
ZIP/Postal Code
31096
Country
Israel
Facility Name
Rabin Medical Center Beilinson Campus
City
Petah Tikva
ZIP/Postal Code
49100
Country
Israel
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel
Facility Name
NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik
City
Bialystok
ZIP/Postal Code
15540
Country
Poland
Facility Name
Niepubliczny Zaklad Opieki Zdrowotnej Centrum Osteoporozy i Chorób Kostno-Stawowych J. Badurski S.J
City
Bialystok
ZIP/Postal Code
15879
Country
Poland
Facility Name
Centrum Badan Klinicznych PI-House Sp. Z o.o
City
Gdansk
ZIP/Postal Code
80546
Country
Poland
Facility Name
Synexus Polska Sp. z o.o. Oddzial w Gdyni
City
Gdynia
ZIP/Postal Code
81384
Country
Poland
Facility Name
Synexus Polska Sp. z o.o. Oddzial w Katowicach
City
Katowice
ZIP/Postal Code
40040
Country
Poland
Facility Name
Specjalistyczny Osrodek ALL-MED
City
Krakow
ZIP/Postal Code
31023
Country
Poland
Facility Name
Krakowskie Centrum Medyczne
City
Krakow
ZIP/Postal Code
31501
Country
Poland
Facility Name
Center Med
City
Krakow
ZIP/Postal Code
31530
Country
Poland
Facility Name
Specjalistyczne Gabinety Lekarskie "Dermed
City
Lodz
ZIP/Postal Code
90265
Country
Poland
Facility Name
Centrum Medyczne SYNEXUS POZNAN
City
Poznan
ZIP/Postal Code
60702
Country
Poland
Facility Name
Centrum Medyczne Medyk
City
Rzeszow
ZIP/Postal Code
35055
Country
Poland
Facility Name
SANUS Szpital Specjalistyczny Sp. z o.o
City
Stalowa Wola
ZIP/Postal Code
37450
Country
Poland
Facility Name
EuroMedis Sp. z o.o.
City
Szczecin
ZIP/Postal Code
70111
Country
Poland
Facility Name
NZOZ "Nasz Lekarz" Praktyka Grupowa Lekarzy z Przychodnia Specjalistyczna
City
Torun
ZIP/Postal Code
87100
Country
Poland
Facility Name
Synexus Polska Sp. z o.o. Oddzial w Warszawie
City
Warszawa
ZIP/Postal Code
01192
Country
Poland
Facility Name
MTZ Clinical Research Sp. z o.o.
City
Warszawa
ZIP/Postal Code
02106
Country
Poland
Facility Name
Synexus Polska sp. z o.o
City
Wroclaw
ZIP/Postal Code
50088
Country
Poland
Facility Name
Dermmedica Sp. z o.o
City
Wroclaw
ZIP/Postal Code
51318
Country
Poland
Facility Name
Vincent Pallotti Hospital
City
Pinelands
State/Province
Cape Town
ZIP/Postal Code
7405
Country
South Africa
Facility Name
Synopsis Research
City
Rondebosch
State/Province
Cape Town
ZIP/Postal Code
7700
Country
South Africa
Facility Name
Jongaie Research
City
Pretoria West
State/Province
Pretoria
ZIP/Postal Code
0183
Country
South Africa
Facility Name
Helderberg Clinical Trial Centre
City
Somerset West
State/Province
Western Cape
ZIP/Postal Code
7130
Country
South Africa
Facility Name
Dr IC Louw
City
Cape Town
ZIP/Postal Code
7500
Country
South Africa
Facility Name
Winelands Rheumatology Centre
City
Stellenbosch
Country
South Africa
Facility Name
Clinical Projects Research
City
Worcester
ZIP/Postal Code
6850
Country
South Africa

12. IPD Sharing Statement

Learn more about this trial

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

We'll reach out to this number within 24 hrs